GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
63.84 USD   +0.90%
05/19Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
BU
05/19Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nearly 7% in Shanghai, Hong Kong
MT
05/18China Junshi's potential COVID drug shows promise in small trial
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about GILEAD SCIENCES, INC.
05/19Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Progr..
BU
05/19Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nea..
MT
05/18China Junshi's potential COVID drug shows promise in small trial
RE
05/17Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Car..
BU
05/17Gilead Sciences, Inc. - FDA Lifts Clinical Hold on Investigational Lenacapavir for the ..
AQ
05/17WALL STREET STOCK EXCHANGE : Finding the tipping point
05/17ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...
05/17Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral ..
MT
05/16Gilead Sciences Says FDA Lifts Hold on Investigational Lenacapavir to Treat HIV
MT
05/16FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention..
BU
05/16U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir fo..
CI
05/16Gilead Sciences Says FDA Lifts Clinical Hold On Injectable Lenacapavir
DJ
05/13UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating
MT
05/11New class of cancer drugs down, not out, after Roche trial setback - analysts
RE
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
05/10TRANSCRIPT : Gilead Sciences, Inc. Presents at Bank of America 2022 Healthcare Conference,..
CI
05/05GILEAD SCIENCES, INC. : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
05/05Declaration of Voting Results by Gilead Sciences, Inc
CI
05/05Declaration of Voting Results by Gilead Sciences, Inc
CI
05/05Declaration of Voting Results by Gilead Sciences, Inc
CI
05/05Declaration of Voting Results by Gilead Sciences, Inc
CI
05/05Declaration of Voting Results by Gilead Sciences, Inc
CI
05/05Declaration of Voting Results by Gilead Sciences, Inc
CI
05/05Curebase, Inc. announced that it has received $40 million in funding from a group of in..
CI
05/04GILEAD SCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/04Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25,..
CI
05/04Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 2, ..
CI
05/02Gilead Sciences, Dragonfly Sign Strategic Research Deal to Develop Natural Killer Cell ..
MT
05/02Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Kille..
BU
05/02Gilead Sciences, Inc. and Dragonfly Announce Strategic Research Collaboration to Develo..
CI
04/29BMO Capital Adjusts Gilead Sciences Price Target to $63 From $65, Maintains Market Perf..
MT
04/29Piper Sandler Adjusts Gilead Sciences' Price Target to $73 From $72, Maintains Neutral ..
MT
04/28GILEAD SCIENCES : View First Quarter 2022 Supplementary Info
PU
04/28GILEAD SCIENCES : ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS - Form 8-K
PU
04/28GILEAD SCIENCES : View First Quarter 2022 Summary of Remarks
PU
04/28Gilead Sciences Seeks Acquisitions
CI
04/28TRANSCRIPT : Gilead Sciences, Inc., Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28GILEAD SCIENCES : View First Quarter 2022 Earnings Release
PU
04/28GILEAD : Q1 Earnings Snapshot
AQ
04/28Gilead Sciences Q1 Adjusted EPS, Revenue Rise; Company Reaffirms 2022 Outlook
MT
04/28Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 Revenue $6.59B, vs. Street Est of $6.2..
MT
04/28Gilead Sciences Announces First Quarter 2022 Financial Results
BU
04/28Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 EPS $2.12, vs. Street Est of $1.81
MT
04/28Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
04/28Gilead Sciences, Inc. Declares Quarterly Cash Dividend for the Second Quarter of 2022, ..
CI
04/28Gilead Sciences, Inc. Revises Earnings Guidance for the Fiscal Year 2022
CI
04/28EARNINGS REACTION HISTORY : Gilead Sciences, 63.6% Follow-Through Indicator, 2.9% Sensitiv..
MT
04/27Big Biotech Firms Have Several Catalysts Lined Up, UBS Says
MT
04/26J&J sues to block sales of 'dangerous' counterfeit HIV drugs
RE
04/26Gilead Sciences to Present at Upcoming Investor Conferences
BU
04/26Gilead Sciences, Inc. - Veklury (Remdesivir) is First and Only Approved Treatment for P..
AQ
04/25Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under..
BU
04/25Gilead Sciences Announces Veklury® is First and Only Approved Treatment for Pediatric P..
CI
04/25U.S. FDA approves Gilead's COVID-19 drug for young children
RE
04/25U.S. FDA approves Gilead's COVID-19 drug remdesivir for young children
RE
04/25FDA Approves Gilead's Veklury as First Covid-19 Treatment for Young Children
DJ
04/25Several New Studies Presented at ECCMIC 2022 Confirm Veklury (Remdesivir) Activity in T..
AQ
04/24Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in ..
BU
04/24Gilead Sciences, Inc. Announces Findings from Two Studies, Which Provide Further Insigh..
CI
04/22Gilead Statement on WHO Recommendation of Veklury (Remdesivir) and Acceleration of Preq..
AQ
04/22Gilead Sciences' Veklury Recommended by WHO for High-Risk COVID-19 Patients
MT
04/21GILEAD SCIENCES : Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleratio..
PU
04/21WHO backs Pfizer's oral COVID therapy for high-risk patients
RE
04/21WHO backs Pfizer's oral COVID therapy for high-risk patients
RE
04/19Gilead Sciences' Kite Pharma Says it has FDA Approval for Commerical Production of Canc..
MT
04/19Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturin..
BU
04/19Demand for Pfizer's COVID pills lags around the world
RE
04/18Lupin Gets US FDA's Tenttive Approval for Hepatitis B Drug
MT
04/14Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, ..
BU
04/14TRANSCRIPT : Gilead Sciences, Inc. - Special Call
CI
04/13FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
AQ
04/13GSK to buy Sierra Oncology amid pressure to boost drug pipeline
RE
04/13GlaxoSmithKline plc entered into an agreement to acquire Sierra Oncology, Inc. for $1.3..
CI
04/12Morgan Stanley Lowers Gilead Sciences Price Target to $63 From $69, Maintains Euqalweig..
MT
04/12GLOBAL MARKETS LIVE : Honda, Shopify, Meta, ASOS, Gilead Sciences...
1  2  3  4  5  6  7  8  9  10Next
Official Publications
Upcoming event on GILEAD SCIENCES, INC.